	US 11,785,923 B2
	Genetically modified non-human animals and methods relating to complement dependent cytotoxicity
Leonard D. Shultz, Bar Harbor, ME (US); Mohit Kumar Verma, Bar Harbor, ME (US); Dale L. Greiner, Hubbardston, MA (US); and Michael A. Brehm, Dudley, MA (US)
Assigned to The Jackson Laboratory, Bar Harbor, ME (US); and University of Massachusetts, Boston, MA (US)
Filed by The Jackson Laboratory, Bar Harbor, ME (US); and University of Massachusetts, Boston, MA (US)
Filed on May 28, 2020, as Appl. No. 16/886,289.
Application 16/886,289 is a continuation of application No. 15/736,951, granted, now 10,701,911, previously published as PCT/US2016/037882, filed on Jun. 16, 2016.
Claims priority of provisional application 62/326,958, filed on Apr. 25, 2016.
Claims priority of provisional application 62/180,369, filed on Jun. 16, 2015.
Prior Publication US 2020/0359609 A1, Nov. 19, 2020
Int. Cl. A01K 67/027 (2006.01); C12N 15/90 (2006.01); C07K 14/47 (2006.01); A61K 49/00 (2006.01)

CPC A01K 67/0275 (2013.01) [A01K 67/027 (2013.01); A01K 67/0271 (2013.01); A61K 49/0008 (2013.01); C07K 14/472 (2013.01); C12N 15/907 (2013.01); A01K 2207/12 (2013.01); A01K 2207/15 (2013.01); A01K 2217/07 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0387 (2013.01)]

12 Claims

1. An immunodeficient mouse, wherein the genome of the mouse comprises a non-obese diabetic (NOD) background and an endogenous wild-type Mus musculus Hc¹Allele encoding a functional C5 complement component structural protein, and wherein the functional C5 complement component structural protein is expressed in the mouse.

10. A method for producing a mouse model system for assessment of an anti-cancer therapeutic or putative anti-cancer therapeutic, comprising:

administering xenograft tumor cells to the immunodeficient mouse of claim 1.

11. A method for assessing the effect of an anti-cancer therapeutic antibody or putative anti-cancer therapeutic antibody, comprising:

administering xenograft tumor cells to the immunodeficient mouse of claim 1;

administering an anti-cancer therapeutic antibody or putative anti-cancer therapeutic antibody to the immunodeficient mouse; and

assaying a response of the xenograft tumor cells to the anti-cancer therapeutic antibody.